Novel Inhibitors of MPNST
Abstract
Mutations in NF1 lead to the aberrant activation of the Ras oncoproteins. Upregulated Ras activity promotes the development of potentially lethal MPNST in NF1 patients. Genetic and pharmaceutical anti-Ras approaches can inhibit MPNST in experimental systems of NF1 dysfunction. However, currently there are no anti-Ras therapeutics that are clinically effective. The development of such agents could revolutionize treatment options for NF1 disease. We have developed two small molecules, one a direct and one an indirect inhibitor of Ras function. We have confirmed that these two molecules are active against MPNST tumor cells in vitro. Moreover, we have shown that they have low toxicity and are active against Ras driven tumor cell systems in vivo. Here, we seek to test the molecules against MPNST model systems in vivo.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2020
- Accession Number
- AD1110006
Entities
People
- Geoffrey J. Clark
Organizations
- University of Louisville